Table 5 |
||
|
All-cause adverse events |
||
|
Placebo N = 248 |
Pregabalin N = 250 |
|
|
|
||
|
Adverse events |
175 (70.6)a |
225 (90.0) |
|
Serious adverse events |
1 (0.4) |
3 (1.2) |
|
Severe adverse events |
0 |
2 (0.8) |
|
Discontinuations due to adverse events |
9 (3.6) |
24 (9.6) |
|
Dose reductions/temporary discontinuations due to adverse events |
11 (4.4) |
30 (12.0) |
|
Frequent adverse eventsb |
||
|
Somnolence |
45 (18.1) |
116 (46.4) |
|
Dizziness |
15 (6.0) |
74 (29.6) |
|
Nasopharyngitis |
45 (18.1) |
45 (18.0) |
|
Increased weight |
9 (3.6) |
39 (15.6) |
|
Constipation |
17 (6.9) |
36 (14.4) |
|
Feeling abnormal |
3 (1.2) |
20 (8.0) |
|
Peripheral edema |
3 (1.2) |
18 (7.2) |
|
Headache |
15 (6.0) |
15 (6.0) |
|
Vision blurred |
3 (1.2) |
13 (5.2) |
|
|
||
|
aNumber (%) of patients. bReported by ≥5% of patients in any group. |
||
|
Ohta et al. Arthritis Research & Therapy 2012 14:R217 doi:10.1186/ar4056 |
||
